Download App

Log in to access Online Inquiry
Company Overview More
Heplatinum Pharmaceutical Holdings Co., Ltd. is an investment holding company mainly engaged in the development of innovative therapies in the field of tumor immunology and immune diseases. The company's products include bartolizumab, mainly for immune thrombocytopenia, thyroid associated ophthalmopathy, myasthenia gravis, optic neuromyelitis spectrum diseases, and tenacil, mainly for dry eye diseases. In addition, the company also studies and develops tumor immunization product lines, including internally developed new-generation tumor immune assets for the treatment of immune desert, immune rejection and inflammatory tumors.
CEO: Jingsong Wang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > 02142 HBM HOLDINGS-B > Detailed Quotes

02142 HBM HOLDINGS-B

3.670-0.210-5.41%
Market Close 05/24 16:08 CCT
High
3.940
Open
3.900
Turnover
7.51M
Low
3.630
Pre Close
3.880
Volume
2.00M
Market Cap
2.82B
P/E(TTM)
Loss
52wk High
12.400
Shares
767.89M
P/E(Static)
Loss
52wk Low
3.080
Float Cap
2.82B
Bid/Ask %
41.91%
Historical High
12.400
Shs Float
767.89M
Volume Ratio
0.72
Historical Low
3.080
Dividend TTM
--
Div Yield TTM
--
P/B
1.62
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.26%
Amplitude
7.99%
Avg Price
3.744
Lot Size
1000
Float Cap
2.82B
Bid/Ask %
41.91%
Historical High
12.400
Shs Float
767.89M
Volume Ratio
0.72
Historical Low
3.080
Dividend TTM
--
P/B
1.62
Dividend LFY
--
Turnover Ratio
0.26%
Amplitude
7.99%
Avg Price
3.744
Lot Size
1000
Price Forecast

No Data

News

Comment

No More